Bank Central Asia BBCA IJ - Buy - Solid YTD Jul-24 results
BBCA’s bank-only Jul-24 earnings of IDR4.9tr (+1% m-m / +17% y-y) brings YTD Jul-24 headline profit to
Lower TP to IDR5,400 (from IDR6,300)
In our recent note on BBRI, we wrote that the bank may face maturing micro/ultra-micro segments in coming years. This suggests that future growth will be structurally slower and thus, we think that BBRI may need to refocus growth in corp/commercial segments, at least in the medium term (~3 years). Moreover, we also anticipate larger write-offs for micro/ultra micro segments as well for 2024-26F. So far, we believe these may have been the primary reasons for substantial selling pressure in 2024 for the stock, which may persist in the near term. Going into 2025F, we think the bank will likely have a slower Kupedes disbursement (although the bank is still in discussion with the government to set the target for 2025). We anticipate 1) smaller KUR disbursement targets; and/or 2) potential changes in the insurance schemes, which could also mean some adjustments to the effective lending rates that BBRI could earn. Still, this may ease NPL pressures for the bank (excluding those write-offs that may be needed associated with past KUR disbursements made in the 2020-2022 period). Still, we think smaller KUR disbursement targets could provide greater earnings visibility for BBRI. However, in this report, we use more conservative earnings projections, which primarily reflect: 1) higher loan write-offs and hence higher credit cost assumptions (by 10-20bp for 2025-26F), as well as 2) lower loan growth projections of 7.5% pa for the 2025-26F period. These have translated into earnings forecast downgrades by 4-5% in 2025-26F. Refer to the figures inside for more details. We expect the stock might underperform other large Indonesian banks, but maintain our Buy rating. Having said that, we have seen more stable loan write-off trends (albeit still elevated). This suggests elevated credit costs in 2025-26F.
Valuation and risks We derive our TP of IDR5,400 based on DuPont analysis, with a risk-free rate of 6.5%, an equity risk premium of 7.8%, growth of 9.3% (cut from 10.0%), beta 0.8x and a CAR-adjusted ROAE of 18.0%. We have also used 2025F book as reference. The implied multiples at our TP would be 2.5x 2025F book and 13.1x 2025F earnings. Risks are worsening macroeconomic trends, unfavorable regulatory changes, and tighter liquidity competition, which could increase funding costs, worsening credit quality which would raise credit costs, and higher opex. Changes in management may affect the bank’s write-off policies and thus, credit costs. This would ultimately affect near term earnings for the bank.
Year-end 31 Dec | FY23 | FY24F | FY25F | FY26F | |||
Currency (IDR) | Actual | Old | New | Old | New | Old | New |
PPOP (bn) | 106,352 | 115,175 | 115,112 | 120,977 | 119,003 | 126,757 | 123,805 |
Reported net profit (bn) | 60,100 | 61,848 | 61,799 | 64,590 | 62,313 | 67,236 | 63,695 |
Normalised net profit (bn) | 60,100 | 61,848 | 61,799 | 64,590 | 62,313 | 67,236 | 63,695 |
FD normalised EPS | 398.24 | 409.82 | 409.49 | 427.99 | 412.90 | 445.52 | 422.06 |
FD norm. EPS growth (%) | 17.8 | 2.9 | 2.8 | 4.4 | 0.8 | 4.1 | 2.2 |
FD normalised P/E (x) | 10.2 | – | 9.9 | – | 9.8 | – | 9.6 |
Price/adj. book (x) | 2.0 | – | 1.9 | – | 1.8 | – | 1.7 |
Price/book (x) | 2.0 | – | 1.9 | – | 1.8 | – | 1.7 |
Dividend yield (%) | 7.8 | – | 7.9 | – | 8.1 | – | 8.1 |
ROE (%) | 19.7 | 19.4 | 19.4 | 19.4 | 18.8 | 19.3 | 18.5 |
ROA (%) | 3.1 | 3.0 | 3.0 | 2.9 | 2.8 | 2.7 | 2.6 |
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Rating Remains | Buy |
Target price Reduced from IDR 6,300 | IDR 5,400 |
Closing price 20 December 2024 | IDR 4,060 |
Implied upside | +33.0% |
Market Cap (USD mn) | 37,626.7 |
ADT (USD mn) | 81.6 |
M cap (USDmn) | 37,626.7 |
Free float (%) | 43.3 |
3-mth ADT (USDmn) | 81.6 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | -6.2 | -24.5 | -26.8 |
Absolute (USD) | -8.1 | -29.3 | -29.9 |
Rel to Jakarta Stock Exchange Composite Index | -3.5 | -14.7 | -23.6 |
Nicholas Santoso (nicholas.santoso@verdhana.id)
Erwin Wijaya (erwin.wijaya@verdhana.id)